COMBINATION OF CRIZOTINIB AND OSIMERTINIB IN T790M+ EGFR-MUTANT NON-SMALL CELL LUNG CANCER WITH EMERGING MET AMPLIFICATION POST-OSIMERTINIB PROGRESSION IN A 10-YEAR SURVIVOR: A CASE REPORT

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor Cafetiere (EGFR) mutations.The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as

read more

Induction of Covalently Crosslinked p62 Oligomers with Reduced Binding to Polyubiquitinated Proteins by the Autophagy Inhibitor Verteporfin.

Autophagy is a cellular catabolic process responsible for the degradation of cytoplasmic constituents, including organelles and long-lived proteins, that helps maintain cellular homeostasis and protect against various cellular stresses.Verteporfin is a benzoporphyrin derivative used clinically in photodynamic therapy Cafetiere to treat macular dege

read more